RxDoctor Payments Data

Roxana Bodin, MD

Gastroenterology · Valhalla, NYNPI 1215254602

Payments from drug & device makers

$102,246in general payments, 2019–2025

Across 106 payments — averaging $964.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$101K
  • Gilead$333
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$149
  • Aimmune Therapeutics, Inc.$135
  • AbbVie$128
  • Takeda Pharmaceuticals U.S.A., Inc.$97
  • plus $465 from 10 others

What the payments were for

  • Speaking & faculty fees$96,59694%
  • Travel & lodging$1,7032%
  • Food & beverage$3,9484%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$102,246 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$5,321
Medicare patients
26
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir13$317,506
XifaxanRifaximin45$163,954
MounjaroTirzepatide28$30,031
Tacrolimus72$10,210
Envarsus XrTacrolimus11$7,187
Ursodiol35$7,094
Mycophenolate Mofetil14$919
Lactulose22$617
Pantoprazole Sodium29$556
Midodrine Hcl12$459
Spironolactone37$419
Ciprofloxacin Hcl18$331
Gabapentin14$315
Rosuvastatin Calcium12$203
Metoprolol Succinate15$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa$333$317,50613 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$149$163,95445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Valhalla

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →